Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBV 001
- Development stage
- Preclinical
- Lead developer
- ResVita Bio
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
**RBV 001** is an autologous vascular endothelial stem cell therapy being developed by Revascular Bio for **digital ulcers associated with systemic sclerosis**. The program uses **CD157-positive vascular endothelial stem cells** derived from the patient, with the intended therapeutic rationale of promoting vascular repair, neovascularization, and tissue regeneration in ischemic or poorly healing lesions. Revascular Bio's pipeline identifies RBV 001 as a **preclinical** program; no discrete molecular target, route of administration, dosage form, or branded name has been publicly disclosed.
- Other names
- autologous cell therapy vascular endothelial stem cells CD157+
Beyond the preview
Go deeper on RBV 001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBV 001.